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Abstract
Parkinson’s disease (PD) is characterized by the activation of degenerative and
inflammatory processes in brain circuits that control movement and, according to the
degree of progression of the damage, can cause neuropsychological disorders such as
cognitive dysfunction. Changes in gene expression profile or post-translational mod-
ifications in secretory proteins such as neurotrophic factors could define the disease
progression. Brain-derived neurotrophic factor (BDNF) is relevant, because it not
only participates in neuronal survival, neurotransmission, dendritic growth and
cellular communication but also in disease progression. In this chapter, considering
both experimental evidences and clinical reports, the authors will analyze the contri-
bution of BDNF as one of the causes of neurodegeneration and neuroinflammation;
discuss the participation of this neurotrophic factor in the development of cognitive
dysfunction, and finally the scope of novel BDNF-based therapies for PD.
Keywords: neurodegeneration, regeneration, BDNF, therapy, cognitive
dysfunction
1. Introduction
Parkinson’s disease is the second most common neurodegenerative disease
worldwide, with high annual costs of treatment. The death of dopaminergic neu-
rons and inflammation are the main cellular processes associated with motor and
cognitive dysfunctions in PD [1–4]; these events can be potentiated by the loss of
the brain-derived neurotrophic factor (BDNF), a key neurotropic factor in degen-
eration and regeneration processes.
1
2. BDNF
2.1 Sources
BDNF, discovered in 1982, is a pleiotropic neurotrophin (NT). The gene
encoding for BDNF is located on chromosome 11p14.1. Under normal conditions,
this neurotrophic factor is synthesized as a non-covalently bound homodimer that
contains a signal peptide next to the initiation codon, a pro-region containing an
N-linked glycosylation site, and interacts with its receptor as a homodimer [5].
The BDNF gene, in rodents, consists of nine untranslated 50 exons, each linked to
individual promoter regions, and a 30 coding exon (IX), which encodes the amino
acid sequence of the BDNF pre-protein. Similarly, human BDNF gene also consists
of multiple 50 exons spliced to a single 30 coding exon. The transcription of
neurotrophins is finely regulated by several intracellular signaling pathways and by
different transcription factors [6].
This NT is synthesized as an inactive precursor form, pre-pro-BDNF that can be
cleaved to form a mature neurotrophin that is transported to the plasma membrane
and then released in an unprocessed manner. The “pre” sequence is normally deleted
when it translocates through the Golgi membrane, producing the pro-BDNF of 32 kDa.
Small amounts of a truncated 28 kDa pro-BDNF can also be formed in the endoplasmic
reticulum without interfering with the final levels of active, mature 14 kDa BDNF
(m-BDNF). The N-terminal pro-domain of BDNF facilitates intracellular trafficking
and regulated secretion. After cleavage of N-terminal region, the m-BDNF is released,
although this does not exclude the release of the pro-BDNF form [6].
The BDNF shows affinity for two types of receptors. The first is a 75 kDa
glycoprotein from the family of tumor necrosis factor receptors, represented by p75
NTR and P75 + sortilin receptors, and the second is a receptor from the protein
tropomyosin receptor kinase (Trk) family, which involves the TrkA, TrkB and
TrkC, whose main ligands are neuronal growth factor (NGF), BDNF/neurotrophins
(NT-4 and NT-3), respectively. The p75 receptor binds to the pro-BDNF isoform
and can induce apoptosis and bind non-neurotrophic ligands such as the glycopro-
tein of rabies virus, amyloid peptides and also other pro-neurotrophins; it can also
generate neurite retraction and synaptic weakening and facilitate long-term
depression [6–8]. The m-BDNF binds to TrkB receptors promoting cell survival,
neurite extension and long-term synaptic potentiation and improves learning and
memory; it also promotes synaptic plasticity, neurogenesis, formation of angiogenic
tubes, regulation of neurotransmitter release and dendritic growth [5, 6, 9–11].
2.2 Physiological relevance
At the brain level, BDNF is produced in the hippocampus, amygdala, stria
terminalis, septum, nuclei of the solitary tract and cortex [8, 12], where it regulates
the survival and differentiation of various neuronal populations, including sensory
neurons, cerebellar neurons and spinal motor neurons. However, it was observed
that the brain is not the only source of BDNF, since its expression has been demon-
strated in human immune cells (T or B cells and monocytes), adipose tissue cells,
β-cells, vascular endothelial cells and in blood [13, 14]. Its presence in ovaries has
also been described, where it participates in folliculogenesis [15]; in the heart [16]
and in other organs, it participates in angiogenesis and immunomodulation process
[17]. The presence of BDNF in other organs of the body raises the hypothesis that
exogenous neurotrophic factors provide a symptomatic treatment during the
patient’s disease state rather than a cure for the nervous system disorders that cause
the disease [18].
2
Parkinson’s Disease and Beyond - A Neurocognitive Approach
Alterations of BDNF expression are implicated in the development of a variety
of central nervous system (CNS) diseases, including neurodegenerative disorders,
such as Alzheimer’s, Parkinson’s, Huntington’s disease and amyotrophic lateral
sclerosis, and psychiatric disorders, such as depression and schizophrenia [14, 18].
However, several studies have shown that the therapeutic application of BDNF
prevents neuronal degeneration after axotomy and other forms of neuronal injury
[19–22]. In addition, beneficial effects of BDNF have been reported in animal
models of neurodegenerative diseases. Therefore, BDNF is now considered as a
potential therapeutic agent for human neurodegenerative disease, for example,
motor neuron disease and PD (Figure 1).
3. BDNF in Parkinson’s disease
The cause of PD is linked with several molecular factors related to the survival
and susceptibility of the dopaminergic neurons (DN) of the substantia nigra (SN)
[23–25]. The imbalance in the levels of this neurotrophic factor can affect the motor
and cognitive performance in parkinsonian patients. It has been detected that
BDNF levels decrease in serum as well as in the SN and caudal-putamen nuclei of
patients with PD [26, 27].
Recently, it has been proposed that the detection of a low concentration of
BDNF in serum is a biomarker of the early stages of the disease [28, 29]. The low
concentration of this neurotrophic factor in serum of PD patients may be due to a
low transcription of the BDNF gene. Howells et al. [30] reported that the surviv-
ing DN located in the SN of patients with PD contained low levels of BDNF
Figure 1.
Causative and curative roles of BDNF. Schematic view of cognitive dysfunction mediated by binding of pro-
BDNF to p75NTR receptor leading to apoptotic cell death. Induction of BDNF gene due to the binding of pro-
BDNF to p75NTR + sortilin and mBDNF to TrkB receptors leading to cell survival mediated by NF-κB and
CREB, respectively. BDNF, brain-derived neurotrophic factor; mBDNF, mature BDNF; p75NTR, p75
neurotrophin receptor; NRAGE, p75NTR interacting protein; NRIF, neurotrophin receptor interacting factor;
TRAF, tumor necrosis factor receptor-associated factor; MKK7, mitogen-activated protein kinase kinase 7;
ASK1, apoptotic signal-regulating kinase 1; JNK, c-Jun N-terminal kinase; IRAK, interleukin-1 receptor-
associated kinase; IκB, kappa light polypeptide gene enhancer in B-cell inhibitor; NF-κB, nuclear factor kappa-
light chain enhancer of B cells; TrkB, tropomyosin receptor kinase B; tPA, tissue plasminogen activator; MAPK,
mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositol 3-kinase;
AKT, protein kinase B; PLC-γ, phospholipase C gamma; DAG, diacylglycerol; PKC, protein kinase C; IP3,
inositol triphosphate; CaM, calmodulin; CaMK, calmodulin-dependent protein kinase; CREB, cyclic adenosine
monophosphate response element-binding protein.
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mRNA, suggesting that this condition contribute to the death of DN and to the
development of the disease. To counteract the death of DN, Salehi and
Mashayekhi [31] proposed that BDNF is produced by glial cells that increase their
population as a result of an active response to neurodegeneration, since
they reported an increase in BDNF levels in cerebrospinal fluid of patients
with PD [31].
Currently, well-known mechanisms of microRNAs (miRNAs) play a crucial
role in neurotrophin gene regulation. These miRNAs are short non-coding RNAs
of 22 nucleotides that are coupled to the RNA-induced silencing complex (RISC)
and regulate the degradation of the RNAs [32]. Several miRNAs regulate BDNF
expression and could be directly involved in the survival of DN. It has been
reported that miR-1 represses the levels of BDNF expression through regulatory
sites in the 30-UTR sequence of the gene [33–35]. In addition, miR-1 levels have
been found to be decreased in patients with PD compared with healthy individuals
[36]. The decrease in miR-1 in patients with PD may be due to an activated
mechanism to increase the expression of BDNF and promote the survival of the
remaining DN in the SN.
In this regard, it has also been reported that BDNF is negatively regulated by
the damage induced with neurotoxin in a murine model of Parkinsonism using
MPP+. The MPTP neurotoxin is converted to MPP+ by the enzyme monoamine
oxidase (MAO-B), expressed by astrocytes. The MPP+ is then internalized into
the DN specifically by the dopamine transporter and upon reaching toxic levels
in the mitochondria and inhibits the complex I of the electron transport chain
[37]. Zhang et al. [38] reported that the treatment with MPP+ led to an
increased expression of miR-210-3p and decreased expression of BDNF. To
corroborate the results, they performed the inhibition of miR-210-3p and
observed that the levels of BDNF increased and the survival of the tyrosine
hydroxylase-positive DN of the SN in mice injected with MPTP was also signif-
icantly improved. The regulation of BDNF expression has become a key strategy
for the rescue of damaged DN in PD.
Another factor that alters the secretion of BDNF is the single nucleotide
functional polymorphism Val66Met, whose effect has been widely studied in
humans [39–41]. This polymorphism consists of a substitution of valine amino
acid by methionine at position 66 of the precursor protein (pro-BDNF) causing
a decrease in secretion induced by depolarization [42]. The distribution of
alleles has been reported in several populations, with the Val/Val allele
prevailing (from 59 to 72%), followed by Val/Met (from 25 to 38%) and with a
lower prevalence of the Met/Met allele (from 2 to 4%) [43–45]. The effect of
polymorphism has been studied with controversial results as some groups argue
that there is an advantage of the carriers of the Met/Met allele, by showing a
better cognitive performance than the individuals who presented the Val/
Met allele [44]; other researchers conclude that the fact of carrying at least one
66Met allele has a high prevalence of having a greater cognitive deterioration
when PD is present [43].
One of the main characteristics of PD is the formation of Lewy bodies that are
composed mainly of α-synuclein protein [46]. Recently, it was found that this
protein interacts with the neurotrophic receptor TrkB, inhibiting its internalization
and its correct distribution. This interaction blocks BDNF signaling and results in
increased death of DN induced by the MPTP [47]. In addition, α-synuclein has been
shown to affect the retrograde axonal transport of BDNF and confirm the inhibition
of the signaling pathway in a PD model [48]. The inhibition of this neurotrophic
factor makes them susceptible to the DN of the SN and contributes to the symptoms
observed in PD.
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4. Parkinson: clinical aspects and neurological bases
Currently, PD affects the adult population (˃65 years) and even young people
[49, 50]. Although PD is multifactorial, indisputable signs of the disease include the
progressive degeneration of the DN of the nigrostriatal pathway due to oxido-redox
imbalance, followed by neurodegeneration, neuroinflammation, Lewy bodies’
deposits and the generalized damage of the neural circuits that control movement
[24, 51, 52].
The degenerative process develops mainly in the DN. In humans, the early loss
of dopaminergic neurons from the SN drastically reduces the striatal dopamine
concentration [53, 54]. The origin of the motor and non-motor alterations can be
sporadic due to genetic deregulation. Several genetic alterations have been
described in α-synuclein, SNCA, PINK 1, DJ-1, LRRK2, ATP13A2, PLA2G6, FBX07,
VPS35 and BDNF genes [55, 56]. Independent of the etiologic origin, patients with
PD develop motor and even cognitive dysfunctions.
4.1 Motor impairment
The Parkinson’s motor symptoms are bradykinesia, rigidity, inclined posture
and tremor at rest. Neuroimaging studies suggest that the motor signs of the disease
appear when 50–70% of the DN damage is present [57]. Tremor at rest is the
symptom that is present in more than 70% of the patients with PD; these idiopathic
tremors are more noticeable when the patient is not performing a specific move-
ment [58]. Electrophysiological studies suggest that tremor at rest in PD is gener-
ated by multiple oscillatory circuits that are operating at the same frequencies
(4  6 Hz); this tremor is improved with the administration of levodopa, while
orthostatic tremor, in PD, is characterized by rapid and specific tremors that affect
the legs and trunk when standing. This tremor presents a frequency of 14  18 Hz,
where levodopa has no effect, which indicates that the pathophysiology of ortho-
static tremor in PD might be different from the tremor at rest [59].
The bradykinesia or slowness of movement is manifested by the decrease in
manual dexterity or the difficulty to get up from where they are sitting. Also during
the progress of the disease, patients show postural instability with increased risk of
falls as they take much faster and shorter steps, and postural instability has a poor
response to dopamine treatments [58]. The symptoms of PD are progressive; how-
ever, the rate of progression in motor symptoms is variable according to the period
of development of the disease in which they occur [60].
Other motor imbalance is the hypomimia, which is characterized by the decrease
in facial expression or in the number of eye blinks, blurred vision, altered look,
speech alteration, as well as the presence of dystonia or movement disorders, which
causes involuntary contractions of the muscles, stooped posture, difficulty turning,
kyphosis or scoliosis, which refer to an abnormal curvature of the spine, walking
with the drag of the feet, or “freezing” or inability to move in patients with
advanced stage of PD [59].
In functional magnetic resonance imaging studies (fMRI) of akinetic patients,
changes have been observed during the performance of a complex sequential motor
task, showing a reduced functional magnetic resonance signal in the rostral part of
the supplementary motor area and in the right dorsolateral prefrontal cortex. In
addition, these patients also showed a significant bilateral increase in the activation
of the primary sensorimotor cortex, the premotor cortex lateral, the caudal part of
the supplementary motor area, the inferior parietal cortex and the anterior cingu-
late cortex, and in other cortical motor areas [61]. It has been mentioned that during
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the earliest pathological stage of PD, neuronal degeneration occurs in motor nuclei
of the brainstem, olfactory bulbs and limbic areas; as it proceeds, it continues to the
temporal and paralimbic cortices, as well as to the thalamic nuclei, until reaching
associative areas such as the prefrontal lobes, and to finally involve the first order
and sensory motor areas [62–64].
However, Agosta et al. [65] found that the progression of the disease in
patients with moderate and severe PD shows a small cortical atrophy compared
with healthy individuals; this atrophy involves the thalamus and the prefrontal
cortex; they also report that the loss of gray matter did not significantly worsen in
later stages of the disease, with the thalamus showing this atrophy. They also
observed that a microstructural damage of the white matter (WM) occurs with
the increase in the severity of the disease, involving the brainstem, cerebellum,
thalamocortical, interhemispheric and limbic pathways, as well as the extra motor
association tracts. They correlate the damage in WM with the degree of cognitive
deficit, considering that the damage in WM probably contributes to the more
severe motor and non-motor dysfunctions that occur in patients in later stages.
4.2 Cognitive dysfunction
Parkinson’s disease is associated with multiple cognitive deficits and an
increased risk of dementia, especially in its late stage. In addition, alterations in
visuospatial, attentional, executive and memory functions may occur [66]. Epide-
miological studies show that cognitive impairments are present between 24 and
62% of patients with newly diagnosed PD, and in the long term about 15% of
patients remain cognitively intact [67]. The incidence of dementia is approximately
100 per 100,000 patients per year among patients with PD, suggesting that people
with PD have a three to six times greater risk of developing dementia than people of
the same age without PD [68]. However, the pathophysiological mechanisms
involved in these cognitive deficits are not yet clear.
At present, neurotrophic factors have attracted attention from both clinical and
experimental levels. BDNF is one of the key molecules in the modulation of cerebral
plasticity and can induce long-term potentiation (LTP) through the activation of
signal transduction routes; this LTP plays a key role in the neurophysiological basis
for learning and memory [69]. In experimental animal models, it has been observed
that the inhibition of BDNF signaling in knockout mice can affect spatial learning
and memory; on the contrary, in the general population, it has been observed that at
higher levels of BDNF in the hypothalamus there is a better cognitive function,
including memory [70]. Recently, it has been detected that serum levels of BDNF
decrease significantly in those diseases with cognitive deficits, such as Alzheimer’s
disease, mild cognitive impairment and Huntington’s disease [27, 71, 72].
At the clinical level, there has been an association between serum BDNF levels
and cognitive impairment. For example, one study observed the association
between the decreased levels of BDNF present in cerebrospinal fluid, which con-
tributes to early cognitive deterioration in PD, in particular to executive-attentional
dysfunction [20]. On the other hand, an increase in BDNF concentrations has been
detected in the same sample type of individuals with this pathology with respect to
non-diseased controls [31], which could be due to a glial activation to increase the
synthesis of this neurotrophin in response to brain damage [19]. Some authors have
reported the association between the Val66Met BDNF polymorphism and cognitive
dysfunction in patients with PD [43, 44]; subjects with Met BDNF allele show
decreased cognitive flexibility when compared to homozygous carriers of the Val
BDNF allele [45] (Figure 2).
6
Parkinson’s Disease and Beyond - A Neurocognitive Approach
In basic research, it has been observed that a higher concentration of hippocam-
pal BDNF improves spatial memory in Morris’s water maze [73]. The hippocampus
is an important nucleus for learning and memory consolidation processes, and since
BDNF plays an important role in the neuroplasticity of the hippocampus, the
absence of this neurotrophin might affect the processes of learning and memory in
the short and long term. Also, BDNF as well as TrKB has been shown in animal
models to participate in the survival of DN in the SN [74], which is one of the main
populations affected in PD. Therefore, the deficiency of BDNF, as well as its TrKB
receptor, could be related to the loss of DN and the progression of the disease.
In studies of patients with dopaminergic neurodegeneration, a reduction in
serum BDNF levels was observed, accompanied by a loss of striatal dopamine
transporter (DAT) binding, that is, a positive correlation was found between the
striatal DAT junction and BDNF levels [75]. On the other hand, there are several
reports showing an increase in serum BDNF levels and also improvement in cogni-
tive performance in PD patients, who underwent cognitive rehabilitation, when
compared to a placebo group. These findings suggest that serum BDNF levels may
represent a biomarker for the effects of cognitive rehabilitation in PD patients
affected with mild cognitive impairment [76].
4.3 BDNF and aging in PD
Aging is another important variable that not only leads to the slow progression
of PD but also hampers the medical treatment response [77]. There is aging without
PD, but there is no PD without aging [78], showing decreased dopamine levels,
increased sensitivity to mitochondrial dysfunction, alterations in calcium channel
activity, accumulation of iron and neuromelanin, changes in protein degradation
pathways [79], striatal spine retraction [80] and loss of striatal spine density [81].
With advancing age, the loss of DA neurons is fully expressed in PD genetic models
in C. elegans [82] and human-induced pluripotent stem cells [83]; thus, aging is the
key to the pathogenesis of PD [84]. In PD patients, aging leads to severe gait
disturbances including musculoskeletal rigidity, axial impairment and age-related
dementia [85].
In the brain, next to nigrostriatal pathway, hippocampus is highly sensitive to
aging and BDNF is critically involved in the regulation of age-related hippocampal
Figure 2.
Val 66 Met/G196A BDNF polymorphism in Parkinson’s disease. Schematic representation showing the
structure and location of BDNF gene and the location of single nucleotide polymorphism (SNP) that leads to the
disease. BDNF, brain-derived neurotrophic factor.
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decline [86]. In normal striatum, BDNF maintains dendritic spine density and
synapse function, whereas in aged striatum, impaired BDNF signaling is common,
which is further intensified in BDNF Val66Met SNP individuals [87]. With an
increase in human age, BDNF mRNA levels remained same but TrkB mRNA levels
decreased in hippocampus [88], indicating that BDNF-TrkB system of hippocam-
pus is sensitive to aging [89] and deficiency of BDNF-TrkB signaling leads to the
progression of PD [74]. Recent reports in aged brain suggest a diminished capacity
of aged brain to transcribe, release and/or respond to BDNF [87]. As a result,
treatment with TrkB agonist activates TrkB and downstream signaling cascades in
BDNF-independent manner, which is neuroprotective both in vitro and in vivo [90].
5. Anxiety and depression in PD: BDNF role
At pre-clinical level, alterations in the synthesis and presence of BDNF are
related to psychiatric disorders such as anxiety and depression [91, 92]. PD patients
with Val66Met BDNF and G/G-BDNF-Val66Met polymorphisms are more
predisposed to develop symptoms of anxiety or depression when observed at
genetic level [39]. At the protein level observation, pro-BDNF is a facilitator of
hippocampal long-term depression (LTD), and Val66Met pro-BDNF impairs mem-
ory function but pro-BDNF with Met completely inhibits hippocampal LTD indi-
cating the antagonistic activities of pro-BDNF and BDNF on hippocampal LTD
[93]. A post-mortem study on PD patients who received antidepressant drugs
reported that the treatment with antidepressants can induce BDNF expression in
hippocampus [94]. However, activity-dependent secretion of BDNF and under-
standing the mechanism of p75NTR-pro-BDNF pathway are crucial to completely
understand the hippocampal LTD modulation [93].
In this context, murine models has led to demonstrate the presence of the
Val66MetBDNF polymorphism associated with anxiety-like behavior and signifi-
cant increase of corticosterone, the physiological stress hormone, in serum [95].
Similar to human findings, the decreased production of BDNF in the hippocampus,
amygdala and prefrontal cortex [96, 97] can be reversed with antidepressant drugs
[91]. Whereas Tuon et al. evaluated the anti-depressant effect of BDNF, in a 6-
hydroxydopamine (6-OHDA) murine model, by replacing the pharmacological
therapy with physical exercise and observed a decrease of depressive-like behavior,
which was associated with the restoration of pro-BDNF, BDNF and TrkB receptor
levels both in the hippocampus and the striatum of rats [98].
Despite the importance of BDNF in plasticity and cellular maintenance, the
serum levels of this NT have been studied [99]. Existing evidence shows that low
concentration of BDNF is a risk factor to generate depression in PD patients [100].
6. Therapy using BDNF: experimental approaches and patents in animal
models
In brain, BDNF not only mediates region-specific effects on synaptic function
and neuronal morphology [8] but is also involved in various functions including
aging [101], anxiety [102], chronic pain [103], deafness [104], depression [105] and
long-term memory storage [9]. BDNF is proven to be the best therapeutic gene for
treating metabolic syndrome [106], Friedreich’s ataxia [107], neuropsychiatric or
neurocognitive disorders [108], brain ischemia [109], schizophrenia [110], glau-
coma [111], epilepsy [112], spinocerebellar ataxia typ. 6 [113], Huntington’s disease
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[21], multiple sclerosis [114], amyotrophic lateral sclerosis [115], spinal cord injury
[116], Alzheimer’s disease [22] and PD [117].
Despite encouraging and numerous researches supporting the potential thera-
peutic role of BDNF in non-human primate trials, no satisfactory results were found
in clinical trials due to the disability to cross blood-brain barrier (BBB) and to reach
degenerating neurons as such [118]. Hence, alternative methods like addition of
poly ethylene glycol (PEG), either at N-terminal or at C-terminal, and vector-
mediated BBB drug delivery were done to improve the BDNF distribution for use in
clinical trials [119].
However, very short half-life of BDNF limits the effectiveness as a therapeutic
protein, and thus, exogenous delivery methods are necessary to translate BDNF-
based therapies to the clinic. In this direction, gene delivery methods through viral
vectors have gained lot of attention by researchers in the beginning, but later on, it
was proved that the use of viral vectors in the clinic was proven difficult due to the
limited biodistribution and host immunogenicity [120]. Later on, non-viral and
nanocarrier (liposome and polyplex) mediated gene delivery drew the attention as
nanotechnology offers new possibilities for designing vehicles. Along with the
nanotechnology, proteomics also integrated leading to the production of fusion
protein vectors and mimetics (both protein and non-protein). The outline of the
potential therapeutic role of BDNF in treating neurodegenerative disorders, specific
focus on PD, by various researches (Table 1) and the patents related to BDNF
(Table 2) are tabulated.
Animal
model
(toxin)
Mode of BDNF supply Result/outcome
Mouse
(MPTP)
[121–123]
Intranigral Increased cell survival
Non-peptide mimetics of BDNF
Rat (6-
OHDA)
[117, 124–
127]
Intranigral transplants of human
mesenchymal stem cells (hMSC) secreting
the BDNF protein
Regulated neurotrophic effect and
proved vehicle for the targeted
neurotrophic delivery
Intranigral injections of recombinant
human BDNF in healthy rats
Chronic BDNF did not attenuate
dopaminergic parameters in either
striatum or SN
Intra ventricular infusion Adult brain parenchyma may recruit
and/or generate new neurons
Intranigral neurotensin (NTS)-polyplex
nanocarrier mediated gene delivery
Neurorecovery by neuritogenesis in early
stage of PD
Intranigral recombinant adeno-associated
virus (rAAV) vector-mediated gene
delivery
No signs of neuroprotection
Rat (MPTP)
[128]
Transplanting genetically engineered
fibroblasts expressing BDNF protein
Axonal regeneration
Monkey
(MPTP)
[129]
Intrathecal infusion Less neuronal loss and damage was
observed in SN
Rhesus
monkey
[130, 131]
Stimulation of BDNF secretion by caloric
restriction; physical exercise
Increased neuronal survival and
locomotor activity in both SN and
striatum
Table 1.
Therapeutic research works using BDNF.
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The experimental models of Parkinson give evidence of many recovery strate-
gies to BDNF in situ, however till date exist great limitations to use these findings in
novel therapies. Some pre-clinical and clinical resources have been patented
(Table 2).
7. Clinical perspectives of BDNF-related therapy
The main objectives of experimental and clinical research include better under-
standing and proper diagnosis, developing new treatments and preventing them to
the maximum extent. Currently, there are innumerable experimental pathology
studies dedicated to solve the pathophysiology and possible treatment of PD. Based
on this, clinical trials offer an excellent opportunity to help doctors and researchers
to find better ways in detection, treatment or prevention in a safe way and, there-
fore, offer hope to people suffering from PD. Current studies include genetics,
diagnostic imaging, studies that allow the identification of biomarkers of this dis-
ease, pharmacological treatment methods and various proposals for experimental
therapies [132, 133]. Development and application of deep brain stimulation
through implanting electrodes at specific sites to recover neuronal function is now a
treatment option for some people with advanced PD when patients no longer
respond to medications [134].
Having PD during aging involves rapid progression of motor impairment,
altered mood and cognitive dysfunction. At the cellular level, there is a rapid loss of
function and neuronal survival due to the absence of production of neurotrophic
Assignee/s Inventor (date) Title
Max-Planck Gesellschaft zur
Forderung der Wissenschaften,
Regeneron Pharmaceuticals Inc.
Yves-Alain Barde
(1989)
Brain derived neurotrophic factor
Synergen Inc. Frank Collins
(1990)
Production of biologically active
recombinant members of the NGF/BDNF
family of neurotrophic proteins
Teva Pharmaceutical Industries Ltd. Liat Hayardeny
(2009)
Treatment of BDNF-related disorders
using laquinimod
Center for research and advanced
studies of the national polytechnic
institute
Daniel Martinez-
Fong (2012)
Compositions and methods for Parkinson’s
disease treatment by BDNF-flag gene
transfer through neurotensin polyplex to
nigral dopamine neurons
Curna Inc., The Scripps Research
Institute
Faghini
Mohammad Ali
and Coito Carlos
(2013)
Treatment of brain derived neurotrophic
factor related diseases by inhibition of
natural antisense transcript to BDNF
VDF FutureCeuticals Zbigniew
Pietrzkowski
(2013)
Compositions and methods of BDNF
activation
Meiji Co., Ltd. Midori Natsume
(2015)
Promoting the production for the
composition of the brain-derived
neurotrophic factor
Zhou Yi Zhou Xinfu (2015) Application of brain-derived neurotrophic
factor precursor protein as target for
treating affective disorders
Table 2.
Patents related to BDNF and its therapeutic role.
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factors such as BDNF. In the preclinical phase, some experimental approaches
evaluated in animal models have partially prevented the DN degeneration and
neuroinflammation. However, these approaches have great challenges; the thera-
pies should be specific to one cell population, guarantee biosafety for human use,
low cost and induce a sustained therapeutic effect.
Although BDNF was found to be promising in animal models of PD, no signifi-
cant results from clinical trials are reported [135], and thus, therapeutic usage of
BDNF for PD in humans is not yet reported. However, as BDNF cannot pass
through the BBB, intracranial administration is must and this may be overcome by
delivering BDNF bound to certain molecular carriers that can cross BBB to avoid
intracranial surgery-related complications and long-term effects on behavioral dis-
orders [136]. In this aspect, researchers from University of California have com-
bined BDNF with mesenchymal stem cells (MSC) for treating neurodegenerative
diseases, but no published scientific reports exist on preclinical and clinical trials of
MSC/BDNF stem cell product [137].
8. Conclusion
Brain-derived neurotropic factor is relevant to neuronal maintenance and par-
ticipates in the survival of dopaminergic neurons. The deficit of this neurotrophin is
the key for the pathophysiology of PD because it limits the regeneration of motor
and cognitive circuits. The absence of BDNF could promote the cognitive dysfunc-
tion in vulnerable subjects. The knowledge of the synthesis and delivery routes of
this neurotrophin will allow the search for better therapies focused in patients with
neurodegenerative diseases.
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Glossary
6-OHDA (6-hydroxydopamine) is an analogue of dopamine that produces
high neurotoxicity into catecholaminergic neurons. The intracerebral 6-OHDA
model is widely used to evaluate some Parkinson’s symptoms in rodents.
Cognitive dysfunction is characterized by damage in neuronal circuits that regulate
intellectual function, memory and concentration in humans.
Functional magnetic resonance imaging (fMRI) is a clinical technique to
evaluate function and systems-level structure in living brain.
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Gene delivery is referred as inserting or silencing foreign material into host cells
for eliciting a therapeutic benefit. This can be achieved by vectors which include
viral/non-viral, liposome, nanoparticles and peptides.
Levodopa (L-3, 4-dihydroxyphenylalanine) is a molecule derived from tyrosine
(Y) amino acid, a catecholamine precursor. Levodopa is the drug more widely used
to treat early stage of PD.
Lewy bodies are intracytoplasmic inclusions comprising mainly aggregates of α-
synuclein protein.
Long-term depression (LTD) is lasting of neuronal synapses for a long time
followed by a long patterned stimulus.
Long-term potentiation (LTP) is a result of increased levels of signal transmission
of neurons in learning and memory processes.
MicroRNAs are short sequences of ribonucleotides. These molecules show com-
plementarity and thus with messenger RNAs (mRNAs), thereby degrading their
mRNA targets or preventing their translation into proteins.
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a pro-drug to MPP+
neurotoxin that induces loss of catecholaminergic and GABAergic neurons. The
systemic administration of MPTP is referred as classic model of PD in mouse and
monkeys.
Neurodegeneration means progressive loss of structure and/or function of neu-
rons and finally leading to death.
Neuroinflammation is a highly regulated process that makes the host organism to
deal and eradicate the infection by means of innate and adaptive immune systems.
This includes the activation of immune cells and release of pro or anti-inflammatory
cytokines, thus protecting the nervous tissue.
Neurotrophins are growth factors that regulate the survival and cell differentia-
tion in several processes such as motor control, learning, memory and cognition.
Mitochondrial dysfunction is characterized by the loss of electron transport chain
efficiency leading to reduced synthesis of adenosine-50-triphosphate (ATP) and
increased synthesis of free radicles. This is the characteristic feature of aging and
chronic disorders.
Polymorphism is referred as diverse forms of a gene, formed due to the result of
mutations or epigenetic changes.
Trk (tropomyosin receptor kinase) receptors correspond to membrane receptor
proteins that regulate several biological processes including synaptic strength and
plasticity in nervous system. Till date, TrkA, TrkB and TrkC are recognized as
members of this family.
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